International Journal of Hematology

, Volume 87, Issue 2, pp 210–216

Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group

  • Akio Kohno
  • Yoshihisa Morishita
  • Hiroatsu Iida
  • Masamitsu Yanada
  • Toshiki Uchida
  • Motohiro Hamaguchi
  • Masashi Sawa
  • Isamu Sugiura
  • Kazuhito Yamamoto
  • Shuichi Mizuta
  • Hiroshi Sao
  • Tomoki Naoe
  • Koichi Miyamura
  • For the Nagoya Blood and Marrow Transplantation Group
Original Article

DOI: 10.1007/s12185-008-0020-8

Cite this article as:
Kohno, A., Morishita, Y., Iida, H. et al. Int J Hematol (2008) 87: 210. doi:10.1007/s12185-008-0020-8

Abstract

Acute promyelocytic leukemia (APL) is the most curable subtype of acute myeloid leukemia. Second complete remission (CR2) can be easily achieved with several therapeutic options even after relapse. However, the optimal strategy to treat APL in CR2 is still controversial. We retrospectively compared the outcome of autologous (auto) and allogeneic (allo) hematopoietic stem cell transplantation (HSCT) for patients with APL in CR2 or CR3. Fifteen patients received auto and 13 received allo HSCT between 1999 and 2004 at eight hospitals belonging to the Nagoya Blood and Marrow Transplantation Group. Four-year disease-free survival (DFS) and overall survival (OS) for autografted patients were 68.9 and 75.8%, whereas those for allografted patients were 46.2 (P = 0.350) and 46.2% (P = 0.185), respectively. Three autografted patients and one allografted patient relapsed, and one autografted patient and five allografted patients died without leukemia relapse. Among 14 autografted patients who were evaluated for MRD with molecular analysis, relapse occurred in one with positive MRD (n = 2) and two with negative MRD (n = 12). These data suggest that auto HSCT is very effective for APL in CR2 or CR3, and may be preferable to allo HSCT for a portion of patients. Prospective studies are required to define the role of auto HSCT in the treatment of relapsed APL.

Keywords

Hematopoietic stem cell transplantation Acute promyelocytic leukemia Minimal residual disease 

Copyright information

© The Japanese Society of Hematology 2008

Authors and Affiliations

  • Akio Kohno
    • 1
  • Yoshihisa Morishita
    • 1
  • Hiroatsu Iida
    • 2
  • Masamitsu Yanada
    • 3
  • Toshiki Uchida
    • 4
  • Motohiro Hamaguchi
    • 5
  • Masashi Sawa
    • 6
  • Isamu Sugiura
    • 7
  • Kazuhito Yamamoto
    • 8
  • Shuichi Mizuta
    • 9
  • Hiroshi Sao
    • 2
  • Tomoki Naoe
    • 3
  • Koichi Miyamura
    • 10
  • For the Nagoya Blood and Marrow Transplantation Group
  1. 1.Division of Hematology and OncologyJA Aichi Showa HospitalKonanJapan
  2. 2.Department of HematologyMeitetsu HospitalNagoyaJapan
  3. 3.Department of Hematology and OncologyNagoya University Graduate School of MedicineNagoyaJapan
  4. 4.Department of HematologyNagoya Daini Red Cross HospitalNagoyaJapan
  5. 5.Department of Hematology, Clinical and Research CenterNational Hospital Organization Nagoya Medical CenterNagoyaJapan
  6. 6.Department of HematologyAnjo Kosei HospitalAnjoJapan
  7. 7.Department of HematologyToyohashi Municipal HospitalToyohashiJapan
  8. 8.Department of Hematology and Cell TherapyAichi Cancer Center HospitalNagoyaJapan
  9. 9.Department of HematologyFujita Health University HospitalToyoakeJapan
  10. 10.Department of HematologyJapanese Red Cross Nagoya First HospitalNagoyaJapan

Personalised recommendations